Evidence map›Paper›PMID 26109719›Full record

ArticleJournal of virology2015

Dualtropic CXCR6/CCR5 Simian Immunodeficiency Virus (SIV) Infection of Sooty Mangabey Primary Lymphocytes: Distinct Coreceptor Use in Natural versus Pathogenic Hosts of SIV.

Sarah T C Elliott, Katherine S Wetzel, Nicholas Francella, Steven Bryan, Dino C Romero, Nadeene E Riddick, Farida Shaheen, Thomas Vanderford, Cynthia A Derdeyn, Guido Silvestri and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 50 citations in OpenAlex.

  1. Molecular therapy. Advances · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Sarah T C ElliottDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Katherine S WetzelDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Nicholas FrancellaDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Steven BryanDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Dino C RomeroDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Nadeene E RiddickDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Farida ShaheenDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Thomas VanderfordDepartment of Pathology and Laboratory Medicine and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Cynthia A DerdeynDepartment of Pathology and Laboratory Medicine and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Guido SilvestriDepartment of Pathology and Laboratory Medicine and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Mirko PaiardiniDepartment of Pathology and Laboratory Medicine and Yerkes National Primate Research Center, Emory University, Atlanta, Georgia, USA.
Ronald G CollmanDepartments of Medicine and Microbiology and the Penn Center for AIDS Research, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA collmanr@upenn.edu.
Emory University · USPenn Center for AIDS Research · USUniversity of Pennsylvania · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI SHELLEY L BERGER · 1985 to 2026
$222.3M
Yerkes National Primate Research Center Role of type-I IFN in regulating COVID-19 induced inflammation and pathogenesisP51OD011132 · OD · EMORY UNIVERSITY · PI Joon Sup Lee · 2012 to 2026
$167.0M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
TRAINING IN HIV PATHOGENESIST32AI007632 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Frederic D Bushman, James L. Riley · 2000 to 2026
$10.6M
STUDIES OF NATURAL SIV INFECTION OF SOOTY MANGABEYSR37AI066998 · NIAID · EMORY UNIVERSITY · PI SILVESTRI, GUIDO · 2011 to 2020
$7.7M
Role of V1V2 in HIV transmission and pathogenesisR01AI058706 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DERDEYN, CYNTHIA ANN · 2004 to 2016
$6.7M
HIV: gp120, Chemokine Receptors &Macrophage ActivationR01MH061139 · NIMH · UNIVERSITY OF PENNSYLVANIA · PI COLLMAN, RONALD G · 1999 to 2015
$5.2M
Human Respiratory Tract Microbiome in Health, HIV Infection and HIV Lung DiseaseU01HL098957 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI BUSHMAN, FREDERIC D, COLLMAN, RONALD G · 2009 to 2013
$3.9M
Entry Coreceptor Use & Target Cell Tropism in Nonpathogenic SIV InfectionR56AI091516 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI COLLMAN, RONALD G · 2011 to 2011
$449k
NCI NIH HHS P30 CA016520NHLBI NIH HHS U01 HL098957NIAID NIH HHS P30 AI045008NIAID NIH HHS P30-AI045008NIAID NIH HHS R01 AI058706NIAID NIH HHS R01-AI058706NIAID NIH HHS R37 AI066998NIAID NIH HHS R37-AI066998NIAID NIH HHS R56 AI091516NIAID NIH HHS R56-AI091516NIAID NIH HHS T32 AI007632NIAID NIH HHS T32-AI007632NIH HHS P51 OD011132NIMH NIH HHS R01 MH061139NIMH NIH HHS R01-MH061139
6 · The paper itself

Abstract

unlabelledNatural-host sooty mangabeys (SM) infected with simian immunodeficiency virus (SIV) exhibit high viral loads but do not develop disease, whereas infection of rhesus macaques (RM) causes CD4(+) T cell loss and AIDS. Several mechanisms have been proposed to explain these divergent outcomes, including differences in cell targeting, which have been linked to low expression of the canonical SIV entry receptor CCR5 on CD4(+) T cells of SM and other natural hosts. We previously showed that infection and high-level viremia occur even in a subset of SM that genetically lack functional CCR5, which indicates that alternative entry coreceptors are used by SIV in vivo in these animals. We also showed that SM CXCR6 is a robust coreceptor for SIVsmm in vitro. Here we identify CXCR6 as a principal entry pathway for SIV in SM primary lymphocytes. We show that ex vivo SIV infection of lymphocytes from CCR5 wild-type SM is mediated by both CXCR6 and CCR5. In contrast, infection of RM lymphocytes is fully dependent on CCR5. These data raise the possibility that CXCR6-directed tropism in CCR5-low natural hosts may alter CD4(+) T cell subset targeting compared with that in nonnatural hosts, enabling SIV to maintain high-level replication without leading to widespread CD4(+) T cell loss. IMPORTANCE: Natural hosts of SIV, such as sooty mangabeys, sustain high viral loads but do not develop disease, while nonnatural hosts, like rhesus macaques, develop AIDS. Understanding this difference may help elucidate mechanisms of pathogenesis. Natural hosts have very low levels of the SIV entry coreceptor CCR5, suggesting that restricted entry may limit infection of certain target cells, although it is unclear how the virus replicates so robustly. Here we show that in sooty mangabey lymphocytes, infection is mediated by the alternative entry coreceptor CXCR6, as well as CCR5. In rhesus macaque lymphocytes, however, infection occurs entirely through CCR5. The use of CXCR6 for entry, combined with very low CCR5 levels, may redirect the virus to different cell targets in natural hosts. It is possible that differential targeting may favor infection of nonessential cells and limit infection of critical cells in natural hosts, thus contributing to benign outcome of infection.

Indexed as

Virus InternalizationAnimalsCD4-Positive T-LymphocytesCercocebus atysHEK293 CellsHumansReceptors, CCR5Receptors, CXCRSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusViral TropismReceptors, CCR5Receptors, CXCR

Identifiers

PMID26109719
PMCPMC4542357
OpenAlexW1889479760

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.